2025
Moderate- to High-grade Blunt Liver and Spleen Injuries Warrant Repeat Imaging to Identify Treatable Complications
Perea L, Fletcher K, Morgan M, McNickle A, Fraser D, Rosenthal M, Wang E, Goldenberg A, Hancin E, Smith A, Leoni J, Meizoso J, O’Neil C, Noorbakhsh M, Almahmoud K, Lapham D, Sais E, Cullinane D, Falank C, Maung A, Bhattacharya B, Bjordahl P, Guido J, Dixon A, Carlson A, Udekwu P, Shell C, Bilaniuk J, Nemeth Z, Butts C, Zorn J, Ahmeti M, Briggs S, Haan J, Lightwine K, Oh J, Marshall G, Collom M, Lewis R, Davis G, Ratnasekera A, Okorafor O, Broderick M, Kundi R, Muse T, Mehta C, Collins M, Lawrence J, Jacobson L, Williams J, Ewing K, Narveson J, Lieser M, Streams J, Gadomski S, Berne J, Mederos D, Teichman A, Choron R, Grant J, Frederick N, Evans D, Doris S, Scantling D, Laudon A, Craft P, Kirsch J, Brigode W, Stecher J, Nahmias J, Alvarez C, Mousafeiris V, Mulita F, Turcotte M, Holliday T, Michetti C, Glass N, Jackovich A, Bankhead B, Thompson B, Chowdhury S, Thurston B, Bailey C, Bresz K, Horst M, Bernard A, Hazelton J. Moderate- to High-grade Blunt Liver and Spleen Injuries Warrant Repeat Imaging to Identify Treatable Complications. Annals Of Surgery 2025, 282: 580-591. PMID: 40623163, DOI: 10.1097/sla.0000000000006831.Peer-Reviewed Original ResearchConceptsBlunt liverProspective observational studyBSI patientsNonoperative managementIdentification of complicationsProspective observational study of adult patientsClinical conditionsObservational study of adult patientsRepeated imagingStudy of adult patientsClinical changesInjury-related complicationsTime of diagnosisPatient's clinical conditionImages of patientsBlunt spleenAsymptomatic patientsGrade 4 to 5Adult patientsConsensus guidelinesTreatable complicationsOperative interventionComplicationsPatientsInjury patientsTiming of Disability Diagnosis and Accommodations During Medical School by First-Generation Status, Race, Ethnicity, and Gender
Nguyen M, Green C, Mason H, Pereira-Lima K, Sheets Z, Schroth S, Smeltz L, Moreland C, Betchkal R, Grabowski C, Boatright D, Kim M, Meeks L. Timing of Disability Diagnosis and Accommodations During Medical School by First-Generation Status, Race, Ethnicity, and Gender. Academic Medicine 2025, 100: s124-s130. PMID: 40550131, DOI: 10.1097/acm.0000000000006147.Peer-Reviewed Original ResearchMedical school matriculantsClinical accommodationsSchool matriculantsMedical studentsTime of diagnosisDisability diagnosisModified Poisson regressionAssociated with likelihoodPhases of medical trainingNo significant associationRetrospective cohort studyDiagnosis of disabilityPoisson regressionMedical trainingRelative riskDisability typeCohort studyRequesting accommodationsMedical schoolsSignificant associationGraduation statusAccommodation requestsDisabilityFirst-generation college graduatesTimely diagnosisEnergetics of whole genome doubling and genomic instability
Beck R, Tagal V, Amin S, Bakhoum S, Maley C, Verhaak R, Gomes A, Andor N. Energetics of whole genome doubling and genomic instability. Cancer Letters 2025, 630: 217878. PMID: 40517938, DOI: 10.1016/j.canlet.2025.217878.Peer-Reviewed Original ResearchWhole-genome doublingGenome doublingBuffering deleterious mutationsDeleterious mutationsHaploinsufficient genesGenomic instabilityGenomic alterationsEnergetic constraintsTime of diagnosisCancer cellsMutationsPloidyCancer researchTissue sitesCancerAneuploidyTime of detectionGenomeCellsGenesShed lightImpact of pregnancy history and recency of childbirth on long-term outcomes in young patients with early-stage breast cancer.
Nader Marta G, Zheng Y, Rosenberg S, Dibble K, Mayer E, Poorvu P, Ruddy K, Guzman Arocho Y, Collins L, Peppercorn J, Schapira L, Borges V, Tayob N, Come S, Warner E, Polyak K, Winer E, Partridge A. Impact of pregnancy history and recency of childbirth on long-term outcomes in young patients with early-stage breast cancer. Journal Of Clinical Oncology 2025, 43: e12562-e12562. DOI: 10.1200/jco.2025.43.16_suppl.e12562.Peer-Reviewed Original ResearchYoung Women's Breast Cancer StudyPregnancy historyLong-term outcomesBreast cancerBC subtypesYounger patientsAssociated with worse DRFSManagement of breast cancerPregnancy-related hormonal changesEarly-stage breast cancerLong-term disease outcomesBreast Cancer StudyRecurrence-free survivalMedian Follow-UpEarly breast cancerEarly-stage BCAggressive clinical featuresTime of diagnosisWomen many yearsN1 statusYounger ptsT3 tumorsNodal statusT1 tumorsN0 statusClinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT
Gurnari C, Robin M, Adès L, Aljurf M, Almeida A, Duarte F, Bernard E, Cutler C, Della Porta M, De Witte T, DeZern A, Drozd-Sokolowska J, Duncavage E, Fenaux P, Gagelmann N, Garcia-Manero G, Haferlach C, Haferlach T, Hasserjian R, Hellström-Lindberg E, Jacoby M, Kulasekararaj A, Lindsley R, Maciejewski J, Makishima H, Malcovati L, Mittelman M, Myhre A, Ogawa S, Onida F, Papaemmanuil E, Passweg J, Platzbecker U, Pleyer L, Raj K, Santini V, Sureda A, Tobiasson M, Voso M, Yakoub-Agha I, Zeidan A, Walter M, Kröger N, McLornan D, Cazzola M. Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT. Blood 2025, 145: 1987-2001. PMID: 39970324, DOI: 10.1182/blood.2024025131.Peer-Reviewed Original ResearchAllo-HCTMolecular International Prognostic Scoring SystemGenomic profilingInternational Prognostic Scoring SystemAllogeneic hematopoietic cell transplantationAssociated with superior clinical outcomesMutant hematopoietic cellsNon-transplant therapiesPrognostic scoring systemHematopoietic cell transplantationClinical practiceTime of diagnosisSuperior clinical outcomesEstimate patient survivalIPSS-MAllo-HSCTCell transplantationExpert international panelPatient survivalPredisposition variantsTherapeutic optionsClinical outcomesCurative treatmentGenetic abnormalitiesHematopoietic cellsNatural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes
Rodriguez-Sevilla J, Ganan-Gomez I, Kumar B, Thongon N, Ma F, Chien K, Kim Y, Yang H, Loghavi S, Tan R, Adema V, Li Z, Tanaka T, Uryu H, Kanagal-Shamanna R, Al-Atrash G, Bejar R, Banerjee P, Lynn Cha S, Montalban-Bravo G, Dougherty M, Fernandez Laurita M, Wheeler N, Jia B, Papapetrou E, Izzo F, Dueñas D, McAllen S, Gu Y, Todisco G, Ficara F, Della Porta M, Jain A, Takahashi K, Clise-Dwyer K, Halene S, Bertilaccio M, Garcia-Manero G, Daher M, Colla S. Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes. Nature Communications 2025, 16: 3450. PMID: 40216768, PMCID: PMC11992119, DOI: 10.1038/s41467-025-58662-0.Peer-Reviewed Original ResearchConceptsHematopoietic stem cellsMyelodysplastic syndromeImmune escapeMyelodysplastic syndrome hematopoietic stem cellsNatural killer (NK) cellsAberrant hematopoietic stem cellsEarly-stage myelodysplastic syndromeDevelopment of myelodysplastic syndromeStage of myelodysplastic syndromeAdoptive cell therapyFunctional in vitro studiesNatural killer cellsTime of diagnosisPreclinical in vivo studiesPre-malignant clonesDisease-related comorbiditiesPre-malignant stageSlow down disease progressionRegenerate hematopoiesisClonal cytopeniaNK cellsImmune surveillanceKiller cellsHealthy donorsPharmacological therapyInvestigation of NPM1 mutation frequency in cutaneous blastic plasmacytoid dendritic cell neoplasms
Hamdan H, Siddon A, Ramia de Cap M, Germans S, Cantu M, Fuda F, Vandergriff T, Aggarwal N, Weinberg O. Investigation of NPM1 mutation frequency in cutaneous blastic plasmacytoid dendritic cell neoplasms. Human Pathology 2025, 158: 105766. PMID: 40216030, DOI: 10.1016/j.humpath.2025.105766.Peer-Reviewed Original ResearchConceptsBlastic plasmacytoid dendritic cell neoplasmBPDCN patientsBPDCN casesCutaneous blastic plasmacytoid dendritic cell neoplasmAcute myeloid leukemiaPlasmacytoid dendritic cell neoplasmDendritic cell neoplasmNPM1 mutationsMyeloid sarcomaCell neoplasmsSarcoma patientsImmunohistochemical stainingAbsence of NPM1 mutationsFrequency of NPM1 mutationsBone marrow of patientsLow white blood cell countCutaneous myeloid sarcomaWhite blood cell countMarrow of patientsTime of diagnosisHigher hemoglobin levelsBlood cell countPercentage of involvementSRSF2 mutationsComplex karyotypeReal-World Evidence of Administration of Biologic Agents in Patients with Severe Asthma: An Analysis of the Respiratory Department of University Hospital of Patras Asthma Registry
Papaioannou O, Christopoulos I, Tsiri P, Sampsonas F, Karkoulias K, Lykouras D, Sotiropoulou V, Theohari E, Papalexatos D, Komninos D, Christopoulos A, Tzouvelekis A. Real-World Evidence of Administration of Biologic Agents in Patients with Severe Asthma: An Analysis of the Respiratory Department of University Hospital of Patras Asthma Registry. Journal Of Clinical Medicine 2025, 14: 2174. PMID: 40217624, PMCID: PMC11989620, DOI: 10.3390/jcm14072174.Peer-Reviewed Original ResearchTime of diagnosisOral corticosteroidsSevere asthmaFollow-upBiological agentsBlood eosinophilsAdministration of biological agentsInitiation of biologic treatmentMedian valueTreated with biologic agentsTreated with omalizumabUncontrolled severe asthmaUse of corticosteroidsSevere asthma exacerbationsAsthma outpatient clinicLongitudinal useConsecutive patientsMedian ageDisease phenotypic characteristicsRetrospective studyNever smokersCorticosteroidsAsthma exacerbationsAsthma flaresLung function
2024
Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Ninia J, Verma N, Laird J, Hayman T, Knowlton C, Peters G, Campbell A, Housri N, Feghali K, de Jong D, Park H. Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e51. DOI: 10.1016/j.ijrobp.2024.07.1890.Peer-Reviewed Original ResearchExtensive-stage small cell lung cancerProgression-free survivalSmall cell lung cancerOverall survivalCell lung cancerOligometastatic diseaseChemo-ImmunotherapyLung cancerSuperior progression-free survivalMedian follow-up timePatients treated with CCSites of disease involvementConsolidative thoracic radiotherapyAssociated with improved outcomesChemotherapy-based treatmentStratified Cox proportional hazard regressionsLog-rank testCox proportional hazards regressionDisease burdenTime of diagnosisKaplan-Meier estimatesProportional hazards regressionConsolidation radiotherapyPolymetastatic diseaseOligometastatic patientsRevisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes.
Martino M, Galderisi A, Evans-Molina C, Dayan C. Revisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes. Diabetes 2024, 73: 1769-1779. PMID: 39106185, DOI: 10.2337/db24-0163.Peer-Reviewed Original ResearchB cell functionBeta cell lossType 1 diabetesLoss of B-cell functionCell lossOral glucose tolerance testPreclinical type 1 diabetesEarly stage diseaseBeta cell destructionTime of diagnosisDestruction of B cellsGlucose tolerance testMonths prior to clinical diagnosisAntibody positivityStage diseaseDisease activityAutoimmune destructionB cellsDisease accelerationInsulin therapyTolerance testInsulin secretionSubmaximal stimuliCell destructionGlucose controlCurrent management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.
Odzer N, Pusztai L, Rozenblit M. Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey. Journal Of Clinical Oncology 2024, 42: 1104-1104. DOI: 10.1200/jco.2024.42.16_suppl.1104.Peer-Reviewed Original ResearchMultimodal therapySurgical resectionOverall survivalPrimary tumorRandomized trialsResponse to initial chemotherapyTreated with multimodality therapyOligometastatic breast cancerRecommended surgical resectionLocally advanced cancerPalliative systemic chemotherapyProlonged overall survivalTime of diagnosisRandomized clinical trialsOS benefitSystemic chemotherapyInitial chemotherapyResidual lesionsSurvival benefitNCCN guidelinesReceptor subtypesRetrospective studyTreatment modalitiesMetastatic cancerAblative radiationImpact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico
Azamar-Llamas D, Arenas-Martinez J, Olivas-Martinez A, Jimenez J, Kauffman-Ortega E, García-Carrera C, Papacristofilou-Riebeling B, Rivera-López F, García-Juárez I. Impact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico. PLOS ONE 2024, 19: e0301198. PMID: 38547193, PMCID: PMC10977796, DOI: 10.1371/journal.pone.0301198.Peer-Reviewed Original ResearchConceptsIntensive care unitLT patientsSevere COVID-19COVID-19 vaccineImpact of COVID-19 vaccinationSevere diseaseMetabolic-associated fatty liver diseaseLiver transplant recipientsLiver transplant patientsRisk of severe diseaseRetrospective cohort studyTime of diagnosisMRNA-1273 vaccineRisk of severe COVID-19ChAdOx1 nCoV-19Development of severe COVID-19Immunosuppressive therapyFatty liver diseaseImmunocompromised patientsLT recipientsAd5-nCoVTransplant patientsTransplant recipientsHCV infectionLiver transplantationAutomated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning
Gross M, Haider S, Ze’evi T, Huber S, Arora S, Kucukkaya A, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning. European Radiology 2024, 34: 6940-6952. PMID: 38536464, PMCID: PMC11399284, DOI: 10.1007/s00330-024-10624-8.Peer-Reviewed Original ResearchContrast-enhanced magnetic resonance imagingMagnetic resonance imagingClinical staging systemTime of diagnosisHepatocellular carcinomaClinical dataMortality risk predictionOverall survivalStaging systemRadiomic featuresManagement of hepatocellular carcinomaPersonalized follow-up strategiesAssociated with OSMethodsThis retrospective studyHepatocellular carcinoma patientsBaseline magnetic resonance imagingMRI radiomics featuresIndependent validation cohortHarrell's C-indexRisk predictionFollow-up strategiesHigh-risk groupPredictive risk scoreRadiomics feature extractionMedian timeTotal spine MRI for the preoperative evaluation of adolescent idiopathic scoliosis: Part 2 – spinal cord tumors, dysraphisms, diastematomyelia, and vertebral anomalies
Lee H, Janjua F, Ragab A, Moran J, Haims A, Rubio D, Tuason D, Porrino J. Total spine MRI for the preoperative evaluation of adolescent idiopathic scoliosis: Part 2 – spinal cord tumors, dysraphisms, diastematomyelia, and vertebral anomalies. Current Problems In Diagnostic Radiology 2024, 53: 415-421. PMID: 38262798, DOI: 10.1067/j.cpradiol.2024.01.017.Peer-Reviewed Original ResearchTotal spine MRISpinal cord tumorsAdolescent idiopathic scoliosisCord tumorsSpine MRIIdiopathic scoliosisEvaluation of adolescent idiopathic scoliosisVertebral anomaliesNeural axis abnormalitiesArnold-Chiari malformationTime of diagnosisTethered cordAxis abnormalitiesChiari malformationPreoperative evaluationScreening examinationDiastematomyeliaDysraphismTumorScoliosisAbnormalitiesMRIMalformationsSyringomyeliaCordTotal spine MRI for the preoperative evaluation of adolescent idiopathic scoliosis: part 1
Lee H, Janjua F, Ragab A, Moran J, Haims A, Rubio D, Tuason D, Porrino J. Total spine MRI for the preoperative evaluation of adolescent idiopathic scoliosis: part 1. Current Problems In Diagnostic Radiology 2024, 53: 405-414. PMID: 38246795, DOI: 10.1067/j.cpradiol.2024.01.016.Peer-Reviewed Original ResearchTotal spine MRIAdolescent idiopathic scoliosisSpine MRIIdiopathic scoliosisEvaluation of adolescent idiopathic scoliosisNeural axis abnormalitiesSpinal cord tumorsTime of diagnosisArnold-Chiari malformationCord tumorsTethered cordAxis abnormalitiesChiari malformationPreoperative evaluationScreening examinationVertebral anomaliesScoliosisAbnormalitiesMRIDiastematomyeliaDysraphismSyringomyeliaMalformationsTumor
2023
Kidney Function in Patients With Adrenal Adenomas: A Single-Center Retrospective Cohort Study
Rahimi L, Kittithaworn A, Garcia R, Saini J, Dogra P, Atkinson E, Achenbach S, Kattah A, Bancos I. Kidney Function in Patients With Adrenal Adenomas: A Single-Center Retrospective Cohort Study. The Journal Of Clinical Endocrinology & Metabolism 2023, 109: e1750-e1758. PMID: 38157409, PMCID: PMC11318994, DOI: 10.1210/clinem/dgad765.Peer-Reviewed Original ResearchMild autonomous cortisol secretionNonfunctioning adrenal adenomasFactors associated with chronic kidney diseaseChronic kidney diseaseTime of diagnosisAdrenal adenomaKidney functionSingle-center retrospective cohort studyMultivariate analysisSingle-center cohort study of patientsSingle-center cohort studyIncreased risk of chronic kidney diseaseCohort study of patientsRisk of chronic kidney diseaseAngiotensin II receptor blockersAutonomous cortisol secretionAngiotensin-converting enzyme inhibitorsTreated with adrenalectomyImpact of adrenalectomyIndependent risk factorRetrospective cohort studyII receptor blockersFollow-up periodStudy of patientsConverting Enzyme InhibitorsExploring anxiety as an influencing factor of the impact of exercise and mind-body prehabilitation on cognitive functioning among women undergoing breast cancer surgery
Knoerl R, Sannes T, Giobbie-Hurder A, Frank E, McTiernan A, Winer E, Irwin M, Ligibel J. Exploring anxiety as an influencing factor of the impact of exercise and mind-body prehabilitation on cognitive functioning among women undergoing breast cancer surgery. Journal Of Psychosocial Oncology 2023, 42: 448-456. PMID: 38044630, DOI: 10.1080/07347332.2023.2282021.Peer-Reviewed Original ResearchCognitive functioningWorse cognitive functioningBreast cancer surgerySelf-report measuresTime of diagnosisAssessment of anxietyBreast cancerCancer surgeryCognitive functionGreater anxietyAnxiety managementPrehabilitation interventionsAnxietyLinear modelingFunctioningSignificant anxietyAcademic cancer centerImpact of exerciseImpact of baselinePrevalence of anxietyParticipantsOne-unit decreaseStudy enrollmentLinear regression modelingCancer CenterPrevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study
Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Research And Treatment 2023, 204: 181-185. PMID: 37999916, DOI: 10.1007/s10549-023-07179-5.Peer-Reviewed Original ResearchComprehensive genomic profilingBreast cancerYoung womenGenomic alterationsAdvanced breast cancerPD-L1 expressionTargetable genomic alterationsWorse clinical outcomesTime of diagnosisTumor mutational burdenCross-sectional studyBreast cancer casesFoundation MedicineClinical outcomesPIK3CA mutationsCancer casesEstrogen receptorMutational burdenOlder womenConclusionOur findingsTotal casesBreast tumorsTumor tissueBRCA1 mutationsMicrosatellite instabilityPrevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database
Gish R, Jacobson I, Lim J, Waters-Banker C, Kaushik A, Kim C, Cyhaniuk A, Wong R. Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database. Hepatology 2023, 79: 1117-1128. PMID: 37976395, PMCID: PMC11020024, DOI: 10.1097/hep.0000000000000687.Peer-Reviewed Original ResearchConceptsHBV/HDV infectionLiver complicationsAll-Payer Claims DatabaseClaims databaseRisk of liver-related morbidityHepatitis delta virus infectionPrevalence of HDVDelta virus infectionProportion of patientsTime of diagnosisLiver-related morbidityUS insured populationHDV prevalenceHBV populationsHIV infectionCompensated cirrhosisDecompensated cirrhosisHBV infectionDelayed DiagnosisHDV infectionHepatitis BViral hepatitisHBV/HDVPatient characteristicsSevere formComparison of the Revised 4 Th (2016) and 5 Th (2022) Editions of the World Health Organization (WHO) Classification in a Cohort of Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms (MDS) - a Glam Registry (REGLAM) Analysis
Iastrebner M, Zeidan A, Arbelbide J, Velloso E, Pereira T, Boada M, Crisp R, Pereyra P, Reyes J, Zappa M, perez-Jacobo F, Dela Peña Celaya J, Moreno E, Abello V, Solano M, Cuervo D, Espinosa D, Casas C, Montoya L, Enrico A, Prates V, Chavez E, Ontiveros-Austria J, Kornblihtt L, Leon A, Toledo V, Negri L, Serrano J, Sánchez A, Rodriguez-Zuñiga A, Stevenazzi M, Goldschmidt V, Grille S. Comparison of the Revised 4 Th (2016) and 5 Th (2022) Editions of the World Health Organization (WHO) Classification in a Cohort of Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms (MDS) - a Glam Registry (REGLAM) Analysis. Blood 2023, 142: 5179. DOI: 10.1182/blood-2023-185122.Peer-Reviewed Original ResearchProgression-free survivalTime of diagnosisAcute myeloid leukemiaMDS-MLDOverall survivalMDS patientsMDS-RSInternational Prognostic Scoring SystemLow-risk MDS patientsWorld Health Organization classificationLR-MDS patientsMedian blast countRisk MDS patientsCohort of patientsKaplan-Meier methodPrognostic scoring systemClassification of patientsNon-Hispanic whitesMDS-EB2PFS probabilityWHO 2016Baseline characteristicsBlast countMedian ageMeier method
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply